Mercier, Anne-Kristina http://orcid.org/0009-0005-0915-5070
Sunnåker, Mikael
Ueckert, Sebastian
Pawlik, Tadeusz
Henricson, Emilia
Molodetskyi, Oleksandr
Law, Gordon C.
Parker, Victoria E. R.
Oscarsson, Jan
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment
https://doi.org/10.1007/s40262-023-01306-7
Funding for this research was provided by:
AstraZeneca Mölndal
Article History
Accepted: 4 September 2023
First Online: 6 October 2023
Declarations
:
: This study was sponsored by AstraZeneca. Authors who are employees of AstraZeneca contributed to the conduct of the study and analysis described in the manuscript and assisted with the preparation of the manuscript.
: All authors are employees and shareholders of AstraZeneca.
: This study was conducted in accordance with the ethical principles of the Declaration of Helsinki, consistent with the International Conference on Harmonisation Guideline for Good Clinical Practice and applicable regulatory requirements. The study protocol was approved by the local Independent Ethics Committee.
: All participants provided written informed consent prior to enrolment. The informed consent documents were approved by the local Independent Ethics Committee.
: All authors agree to publication.
: Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at ExternalRef removed.
: Not applicable.
: MS, AKM and VERP contributed to the conception or design of the study. All authors contributed to the acquisition, analysis, or interpretation of data. All authors contributed to the edit and review of the manuscript and approved the final version.